The Food and Drug Administration approved Pfizer's treatment for a rare genetic bleeding disorder, making it the company's first gene therapy to win clearance in the U.S. The agency greenlighted ...
Pfizer's first FDA-approved gene therapy is one of the most expensive medications in the U.S. On April 26, Beqvez (fidanacogene elaparvovec-dzkt) won approval to treat some adults with moderate-to ...
Patients with moderate to severe hemophilia B can now take Pfizer’s BEQVEZ (fidanacogene elaparvovec-dzkt) with the approval of the FDA. Hemophilia B is an inherited bleeding disorder that ...
Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose. The U.S. Food and Drug Administration has approved a gene therapy developed by ...
Pfizer’s first FDA-approved gene therapy is the second such treatment for the inherited bleeding disorder hemophilia B, introducing some competition to a therapeutic area that now has two of the ...
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez; Pfizer), a gene therapy administered in a one-time dose, for certain patients with moderate to severe hemophilia B. The FDA has approved ...
The US Food and Drug Administration (FDA) has approved the gene therapy fidanacogene elaparvovec (Beqvez) for adults with hemophilia B, a rare bleeding disorder that affects almost 4 in 100,000 US ...
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of ...
, opens new tab gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a blood-clotting protein. People with ...
A one-time dose of BEQVEZ has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds (range 0 to 19) after up to three years of follow-up, providing sustained ...